Vizimpro (Dacomitinib) Patent Expiration, LOE Window & CMS Spending

Vizimpro (Dacomitinib) by Pfizer: FDA Orange Book core substance LOE 2032-09-27, 0 AB generics, $2.8M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN211288 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-09-27
Last Listed Patent or Exclusivity Date2032-09-27
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.8M
2024 Medicare Part D Spend$2.6M
2024 Medicaid Spend$236K
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 19.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.